A Study to Assess the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822)

• Status: Completed
• Trial end date: 2006-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

This study will assess the safety and tolerability of single doses of odanacatib (MK0822) when administered with a light breakfast.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• Subject is male and between the ages of 18 and 45

• Subject is within 25% of ideal body weight and weighs between 55 and 95 kg

• Subject is in generally good health

• Subject is a nonsmoker

Exclusion Criteria:

• Subject has multiple or severe allergies to food or medications

• Subject has a history of metabolic bone disease, kidney/bladder stones, or treatment with bisphosphonates

• Subject has any infections, including HIV

• Subject has donated blood or taken another investigational drug in the last month

• Subject consumes excessive amounts of caffeine or alcohol

• Subject has a history of any illness that may confound the results of the study or pose additional risk in administering the study drug